Home›Trial›NCT06958315

NCT06958315Active, not recruiting

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Study Summary

This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.

Conditions

Atherosclerotic Vascular Disease Heterozygous Familial Hypercholesterolemia

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Diversified Pharma

Study Details

Enrollment219 participants

Primary Completion2027-05-01

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-10-14

What This Trial Means for Biotech Investors

Trial Phase Context

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Primary completion: 2027-05-01

Enrolled: 219 participants

Sponsor Catalyst Profile

Novartis AG (NVS) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVS Full Pipeline →All Companies →

Other Trials from Novartis AG

NCT07206056An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tul…(PHASE1/PHASE2)NCT06905301Implementation Study to Describe and Compare Retention Rate and Adherence to Adj…NCT06799000A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Ad…(PHASE3)NCT05109728A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in C…(PHASE1)NCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Particip…(PHASE3)

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.